Compare Gilead Sciences, Inc. (GILD) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Orion Office REIT Inc — how do they compare? Gilead Sciences, Inc. trades at $146.25 (market cap $182.40B), while Orion Office REIT Inc trades at $2.2 (market cap $125.50M). The key difference: Gilead Sciences, Inc. is far larger — about 1453.4× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays the higher dividend (3.64%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Orion Office REIT Inc for 33 Days on average.
| GILD | ONL | |
|---|---|---|
Market Cap | $182.40B | $125.50M |
Volume | 4,469,821 | 303,276 |
Sector | Health | Real Estate |
52-Week High | $155.80 | $3.00 |
52-Week Low | $116.74 | $1.93 |
Typical Hold Time | 111 Days | 33 Days |
Enterprise Value | $205.46B | $542.43M |
Dividend Yield | 2.23% | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
ONL trades at $2.27, down 2.58% today, with a bearish technical signal from moving averages but bullish oscillators. The company shows declining revenue from $208M in 2022 to $148M in 2025, with persistent net losses widening to -$139M. Analyst consensus is split 50/50 buy/hold, while recent news highlights strategic portfolio repositioning and Q2 2026 earnings beat.
Outlook remains challenged by negative profitability and high debt levels, though low P/B of 0.2 suggests deep value. Key risks include office sector headwinds and cash flow volatility. Investment appeal hinges on successful execution of turnaround strategy amid weak fundamental trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
